The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
Open accessAbstract
BACKGROUND: Adeno-associated virus (AAV)-mediated gene therapy is under investigation as a therapeutic option for persons with hemophilia A. Efficacy and safety data include 3 years of follow-up after a single administration of AAV5-hFVIII-SQ. METHODS: We report durable efficacy, long-term safety, and clinical and biologic results in 15 adults with severe hemophilia A (factor VIII level, ≤1 IU per deciliter) who had received a single infusion of AAV5-hFVIII-SQ at various dose levels. We evaluated the factor VIII level, annualized rate of bleeding events, use of factor VIII, safety, expression kinetics, and biologic markers of AAV transduction for up to 3 years. RESULTS: vg per kilogram) had a median factor VIII expression of 13 IU per deciliter; the median annualized rate of bleeding events was 0, and the median use of factor VIII was reduced from 155.5 infusions to 0.5 infusions per year. Bleeding in target joints resolved in five of six participants. The factor VIII pharmacodynamic profiles reflected cellular turnover in the blood and molecular events leading to episomal DNA stabilization for persistent expression, findings that are consistent with previous observations in two model systems. Transgene-derived human factor VIII (hFVIII) protein activity mirrored native hFVIII in hemostatic ability. No inhibitor development, thromboses, deaths, or persistent changes in liver-function tests were observed. CONCLUSIONS: vg per kilogram of the gene therapy. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795; EudraCT number, 2014-003880-38.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 5 subjects across 3 trials experienced self-limited, vector-infusion reactions at doses of 2 × 1012−6 × 1013 vg/kg, characterized by fever, myalgias, and/or hypotension, which appear consistent with an innate immune response.141,150,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [150]
In the citing paper
“multiple HA and HB trials have demonstrated ≥10-fold variability in FVIII:C/FIX:C with the same vector and dose (Harrington et al., 2020, WFH Virtual Summit, conference).145,149,150,153”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [150]
In the citing paper
“Corticosteroids are the most commonly used agents to resolve transaminitis, however, its relationship with resolution by corticosteroids and T-cell response are not always clear as observed in a hemophilia A trial (28, 105).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [105]
Citations
Cites
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Definitions in hemophilia: communication from the SSC of the ISTH
Blanchette, V. S., Key, N. S., Ljung, L. R., Manco‐Johnson, M. J., van den Berg, H. M., & Srivastava, A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12672 · Cited by 761
Nucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Self-citationAntioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 673
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Research works printed but not linked: 2
- Torres R, Patton K, Holcomb J, Zoog S, Russell C, Vettermann C. Characterization of AAV5-FVIII-SQ vector DNA in human blood by real-time and Droplet Digital PCR. Mol Ther 2019;27(4):Suppl 1:436-436.
- Fong S, Handyside B, Sihn C-R, et al. The potential for induction of ER stress response by an AAV5-based construct of B-domain deleted FVIII is dependent on the strength of the hepatic specific promoter. Mol Ther 2018;26(5):Suppl 1:375-376.
Cited by
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Ozelo, M. C., Mahlangu, J., Pasi, K. J., Giermasz, A., Leavitt, A. D., Laffan, M., Symington, E., Quon, D. V., Wang, J.-D., Peerlinck, K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2113708 · Cited by 417
Self-citationNguyen, G. N., Everett, J. K., Kafle, S., Roche, A. M., Raymond, H. E., Leiby, J., Wood, C., Assenmacher, C.-A., Merricks, E. P., Long, C. T., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-0741-7 · Cited by 424
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
Berntorp, E., Fischer, K., Hart, D. P., Mancuso, M. E., Stephensen, D., Shapiro, A. D., & Blanchette, V. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00278-x · Cited by 328
The once and future gene therapy
Bulaklak, K., & Gersbach, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-19505-2 · Cited by 321
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A
George, L. A., Monahan, P. E., Eyster, M. E., Sullivan, S. K., Ragni, M. V., Croteau, S. E., Rasko, J. E. J., Recht, M., Samelson-Jones, B. J., MacDougall, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104205 · Cited by 243
Hemophilia therapy: the future has begun
Mannucci, P. M. (2020) · Haematologica · doi:10.3324/haematol.2019.232132 · Cited by 223
George, L. A., Ragni, M. V., Rasko, J. E. J., Raffini, L. J., Samelson-Jones, B. J., Ozelo, M., Hazbon, M., Runowski, A. R., Wellman, J. A., Wachtel, K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.001 · Cited by 213
Sabatino, D. E., Bushman, F. D., Chandler, R. J., Crystal, R. G., Davidson, B. L., Dolmetsch, R., Eggan, K. C., Gao, G., Gil-Farina, I., Kay, M. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.004 · Cited by 212
Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A
Mahlangu, J., Kaczmarek, R., von Drygalski, A., Shapiro, S., Chou, S.-C., Ozelo, M. C., Kenet, G., Peyvandi, F., Wang, M., Madan, B., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211075 · Cited by 205
Self-citationViral Vectors in Gene Therapy: Where Do We Stand in 2023?
Lundstrom, K. (2023) · Viruses · doi:10.3390/v15030698 · Cited by 187
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency
Tai, C.-H., Lee, N.-C., Chien, Y.-H., Byrne, B. J., Muramatsu, S.-I., Tseng, S.-H., & Hwu, W.-L. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.005 · Cited by 162
Greig, J. A., Martins, K. M., Breton, C. A., Lamontagne, J., Zhu, Y., He, Z., White, J., Zhu, J., Chichester, J. A., Zheng, Q., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01974-7 · Cited by 163
Durability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 170
Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues
Leebeek, F. W. G., & Miesbach, W. (2021) · Blood · doi:10.1182/blood.2019003777 · Cited by 158
Novel vectors and approaches for gene therapy in liver diseases
Maestro, S., Weber, N. D., Zabaleta, N., Aldabe, R., & González‐Aseguinolaza, G. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100300 · Cited by 159
Adeno-Associated Virus Gene Therapy for Hemophilia
Samelson‐Jones, B. J., & George, L. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033013 · Cited by 150
Mancuso, M. E., Mahlangu, J. N., & Pipe, S. W. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32722-7 · Cited by 139
Fong, S., Yates, B., Sihn, C., Mattis, A. N., Mitchell, N., Liu, S., Russell, C. B., Kim, B. B., Lawal, A., Rangarajan, S., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01751-0 · Cited by 135
Self-citationKlamroth, R., Hayes, G., Andreeva, T., Gregg, K., Suzuki, T., Mitha, I. H., Hardesty, B., Shima, M., Pollock, T., Slev, P., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.287 · Cited by 118
Self-citationNathwani, A. C. (2022) · Hematology · doi:10.1182/hematology.2022000388 · Cited by 135
Pasi, J., Laffan, M., Rangarajan, S., Robinson, T. M., Mitchell, N., Lester, W., Symington, E. M., Madan, B., Yang, X., Kim, B. B., et al. (2021) · Haemophilia · doi:10.1111/hae.14391 · Cited by 98
Self-citationT Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
Valoctocogene Roxaparvovec: First Approval
Blair, H. A. (2022) · Drugs · doi:10.1007/s40265-022-01788-y · Cited by 92
Gene Therapy in Patients with the Crigler–Najjar Syndrome
D’Antiga, L., Beuers, U. H., Ronzitti, G., Brunetti‐Pierri, N., Baumann, U., Giorgio, A. D., Aronson, S. J., Hubert, A., Romano, R., Junge, N., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214084 · Cited by 92
Monahan, P. E., Négrier, C., Tarantino, M. D., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 90
Nucleic acid therapeutics: Past, present, and future
Naeem, S., Zhang, J., Zhang, Y., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102440 · Cited by 91
Long, B. R., Veron, P., Kuranda, K., Hardet, R., Mitchell, N., Hayes, G. M., Wong, W. Y., Lau, K., Li, M., Hock, M. B., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.008 · Cited by 79
Self-citationGene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 80
Rosén, S., Tiefenbacher, S., Robinson, M. M., Huang, M., Srimani, J. K., Mackenzie, D., Christianson, T., Pasi, J., Rangarajan, S., Symington, E. M., et al. (2020) · Blood · doi:10.1182/blood.2020005683 · Cited by 81
Self-citationAdvances in the management of haemophilia: emerging treatments and their mechanisms
Okaygoun, D., Oliveira, D. D., Soman, S., & Williams, R. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00760-4 · Cited by 86
Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 78
Immunological barriers to haematopoietic stem cell gene therapy
Charlesworth, C. T., Hsu, I., Wilkinson, A. C., & Nakauchi, H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00698-0 · Cited by 73
Fischell, J. M., & Fishman, P. S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.747726 · Cited by 67
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A
Madan, B., Ozelo, M. C., Raheja, P., Symington, E., Quon, D. V. K., Leavitt, A. D., Pipe, S. W., Lowe, G., Kenet, G., Reding, M. T., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.04.001 · Cited by 70
Self-citationSrivastava, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.014 · Cited by 71
Delivery technologies for in utero gene therapy
Palanki, R., Peranteau, W. H., & Mitchell, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.11.002 · Cited by 64
Hemophilia Gene Therapy: Approaching the First Licensed Product
Batty, P. A., & Lillicrap, D. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000540 · Cited by 62
von Drygalski, A., Gomez, E., Giermasz, A., Castaman, G., Key, N. S., Lattimore, S., Leebeek, F. W. G., Miesbach, W., Recht, M., Gut, R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008886 · Cited by 63
Innate Immune Response to Viral Vectors in Gene Therapy
Wang, Y., & Shao, W. (2023) · Viruses · doi:10.3390/v15091801 · Cited by 66
Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies
Chu, W. S., & Ng, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658038 · Cited by 59
Lugin, M. L., Lee, R. T., & Kwon, Y. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c03850 · Cited by 63
Wang, L., Breton, C. A., Warzecha, C. C., Bell, P. L., Yan, H., He, Z., White, J., Zhu, Y., Li, M., Buza, E. L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.020 · Cited by 63
Self-citationImpact of novel hemophilia therapies around the world
Ozelo, M. C., & Yamaguti-Hayakawa, G. G. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12695 · Cited by 63
Gene Therapy in Hemophilia: Recent Advances
Rodriguez-Merchan, E. C., Pablo-Moreno, J. A. D., & Liras, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147647 · Cited by 61
Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A
Cook, K., Forbes, S. P., Adamski, K. N., Janice, J., Chawla, A., & Garrison, L. P. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1721508 · Cited by 60
Chandler, R. J., Venturoni, L. E., Liao, J., Hubbard, B. T., Schneller, J. L., Hoffmann, V. J., Gordo, S., Zang, S., Ko, C., Chau, N., et al. (2020) · Hepatology · doi:10.1002/hep.31570 · Cited by 61
Guo, W., Song, X., Liu, J., Liu, W., Chu, X., & Lei, Z. (2024) · Nanomaterials · doi:10.3390/nano14131088 · Cited by 57
Hemophilia A gene therapy: current and next-generation approaches
Pipe, S. W., Gonen-Yaacovi, G., & Segurado, O. G. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2002842 · Cited by 57
World Federation of Hemophilia Gene Therapy Registry
Konkle, B. A., Coffin, D., Pierce, G. F., Clark, C., George, L. A., Iorio, A., Mahlangu, J. N., Naccache, M., O’Mahony, B., Peyvandi, F., et al. (2020) · Haemophilia · doi:10.1111/hae.14015 · Cited by 53
Self-citationDiscussing investigational AAV gene therapy with hemophilia patients: A guide
Sidonio, R. F., Pipe, S. W., Callaghan, M. U., Valentino, L. A., Monahan, P. E., & Croteau, S. E. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100759 · Cited by 54
Transdermal delivery for gene therapy
Singh, P., Muhammad, I., Nelson, N. E., Tran, K. T. M., Vinikoor, T., Chorsi, M. T., D’Orio, E., & Nguyen, T. D. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01138-1 · Cited by 57
2021 clinical trials update: Innovations in hemophilia therapy
Croteau, S. E., Wang, M., & Wheeler, A. P. (2020) · American Journal of Hematology · doi:10.1002/ajh.26018 · Cited by 52
Milani, M., Canepari, C., Liu, T., Biffi, M., Russo, F., Plati, T., Curto, R., Patarroyo-White, S. L., Drager, D., Visigalli, I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30102-3 · Cited by 56
Jang, A., Petrova, B., Cheong, T.-C., Zawadzki, M. E., Jones, J. K., Culhane, A. J., Shipley, F. B., Chiarle, R., Wong, E. T., Kanarek, N., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.08.009 · Cited by 55
Gene therapy: principles, challenges and use in clinical practice
Ay, C., & Reinisch, A. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02368-8 · Cited by 53
Leavitt, A. D., Mahlangu, J. N., Raheja, P., Symington, E. M., Quon, D. V. K., Giermasz, A., Fernández, M. F. L., Kenet, G., Lowe, G., Key, N. S., et al. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102615 · Cited by 50
Self-citationModern therapeutic approaches to liver-related disorders
Gardin, A., Remih, K., Gonzales, E. M., Andersson, E. R., & Strnad, P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.015 · Cited by 51
The More Recent History of Hemophilia Treatment
Franchini, M., & Mannucci, P. M. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1756188 · Cited by 58
Handyside, B., Ismail, A. M., Zhang, L., Yates, B., Xie, L. Y., Sihn, C., Murphy, R., Bouwman, T., Kim, C. K., Angelis, R. D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.001 · Cited by 54
Konkle, B. A., Pierce, G. F., Coffin, D., Naccache, M., Clark, R. C., George, L. A., Iorio, A., O’Mahony, B., Pipe, S. W., Skinner, M. W., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15023 · Cited by 48
Self-citationRoctavian gene therapy for hemophilia A
Samelson‐Jones, B. J., Small, J. C., & George, L. A. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011847 · Cited by 58
A battery-free nanofluidic intracellular delivery patch for internal organs
Yin, D., Wang, P., Hao, Y., Yue, W. W., Jiang, X., Yao, K., Wang, Y., Hang, X., Xiao, A., Zhou, J., et al. (2025) · Nature · doi:10.1038/s41586-025-08943-x · Cited by 58
Self-citationHemophilia Gene Therapy: The End of the Beginning?
Wolf, D. D., Singh, K., Chuah, M., & VandenDriessche, T. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.112 · Cited by 50
Leavitt, A. D., Konkle, B. A., Stine, K. C., Visweshwar, N., Harrington, T. J., Giermasz, A., Arkin, S., Fang, A. F., Plonski, F., Yver, A., et al. (2023) · Blood · doi:10.1182/blood.2022018971 · Cited by 50
Symington, E. M., Rangarajan, S., Lester, W., Madan, B., Pierce, G. F., Raheja, P., Robinson, T. M., Osmond, D., Russell, C. B., Vettermann, C., et al. (2024) · Haemophilia · doi:10.1111/hae.14936 · Cited by 49
Self-citationSelf-organization of sinusoidal vessels in pluripotent stem cell-derived human liver bud organoids
Saiki, N., Nio, Y., Yoneyama, Y., Kawamura, S., Iwasawa, K., Kawakami, E., Araki, K., Fukumura, J., Sakairi, T., Kono, T., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01416-6 · Cited by 56
Enhancing gene transfer to renal tubules and podocytes by context-dependent selection of AAV capsids
Furusho, T., Das, R., Hakui, H., Sairavi, A., Adachi, K., Galbraith-Liss, M. S., Rajagopal, P., Horikawa, M., Luo, S., Li, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54475-9 · Cited by 47
Broekhoff, T. F., Sweegers, C. C. G., Krijkamp, E., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Goettsch, W., & Vreman, R. A. (2021) · Value in Health · doi:10.1016/j.jval.2020.09.021 · Cited by 53
Current developments of gene therapy in human diseases
Liu, F., Li, R., Zhu, Z., Yang, Y., & Lu, F. (2024) · MedComm · doi:10.1002/mco2.645 · Cited by 47
An overview of development in gene therapeutics in China
Wang, D., Wang, K., & Cai, Y. (2020) · Gene Therapy · doi:10.1038/s41434-020-0163-7 · Cited by 45
Fong, S., Handyside, B., Sihn, C., Liu, S., Zhang, L., Xie, L. Y., Murphy, R., Galicia, N., Yates, B., Minto, W. C., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.005 · Cited by 47
Collins, P. W., Obaji, S. G., Roberts, H., Gorsani, D., & Rayment, R. (2021) · Haemophilia · doi:10.1111/hae.14201 · Cited by 43
Exploiting Single-Cell Tools in Gene and Cell Therapy
Bode, D., Cull, A. H., Rubio-Lara, J. A., & Kent, D. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702636 · Cited by 46
Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives
Chernyi, N., Gavrilova, D., Saruhanyan, M., Oloruntimehin, E. S., Karabelsky, A. V., Bezsonov, E. E., & Malogolovkin, A. S. (2024) · Biomolecules · doi:10.3390/biom14070854 · Cited by 48
Samelson‐Jones, B. J., & Arruda, V. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00618 · Cited by 43
Symington, E. M., Rangarajan, S., Lester, W., Madan, B., Pierce, G. F., Raheja, P., Millar, C. M., Osmond, D., Li, M., & Robinson, T. M. (2024) · Haemophilia · doi:10.1111/hae.15071 · Cited by 40
Self-citationHepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates
Verdera, H. C., Collaud, F., Riling, C. R., Sellier, P., Nordin, J. M. L., Preston, G. M., Cagin, U., Fabregue, J., Barral, S., Moya‐Nilges, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26744-4 · Cited by 45
Self-citationFactor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
Bowyer, A. E., & Gosselin, R. C. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1758870 · Cited by 44
Lee, J. H., Han, J. P., Song, D. W., Lee, G. S., Choi, B. S., Kim, M., Lee, Y., Kim, S., Lee, H., & Yeom, S. C. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.008 · Cited by 41
Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns
Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14023 · Cited by 39
Self-citationState‐of‐the‐art 2023 on gene therapy for phenylketonuria
Martinez, M., Harding, C. O., Schwank, G., & Thöny, B. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12651 · Cited by 43
Gene regulation technologies for gene and cell therapy
Butterfield, G. L., Reisman, S. J., Iglesias, N., & Gersbach, C. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.004 · Cited by 46
Yang, F., Patton, K., Kasprzyk, T., Long, B. R., Gupta, S., Zoog, S. J., Tracy, K., & Vettermann, C. (2021) · Gene Therapy · doi:10.1038/s41434-020-00214-w · Cited by 42
Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review
Fu, Q., Hu, L., Shen, T., Yang, R., & Jiang, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226773 · Cited by 43
Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 43
Loo, L., Harris, S., Milton, M., Meena, M., Lembke, W., Berisha, F., Bertholet, S., Dessy, F. J., Dodge, R. W., Fang, X., et al. (2022) · Bioanalysis · doi:10.4155/bio-2022-0081 · Cited by 40
Doerfler, A. M., Park, S. H., Assini, J. M., Youssef, A., Saxena, L., Yaseen, A. B., Giorgi, M. D., Chuecos, M. A., Hurley, A. E., Li, A., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.009 · Cited by 39
Kapelanski‐Lamoureux, A., Chen, Z., Gao, Z., Deng, R., Lazaris, A., Lebeaupin, C., Giles, L., Malhotra, J. D., Yong, J., Zou, C., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.10.004 · Cited by 38
Song, R., Pekrun, K., Khan, T. A., Zhang, F., Paşca, S. P., & Kay, M. A. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.002 · Cited by 36
Butterfield, J. S. S., Yamada, K., Bertolini, T. B., Syed, F., Kumar, S. R. P., Li, X., Arisa, S., Piñeros, A. R., Tapia, A., Rogers, C. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.005 · Cited by 36
Ng, R. C.-L., Jian, M., Ma, O. K.-F., Xiang, A. W., Bunting, M., Kwan, J., Wong, C. W.-K., Yick, L.-W., Chung, S. K., Lam, K. S. L., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03066-y · Cited by 39
Qian, R., Xiao, B., Li, J., & Xiao, X. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.010 · Cited by 37
Xiang, Z., Kuranda, K., Quinn, W. J., Chekaoui, A., Ambrose, R., Hasanpourghadi, M., Novikov, M., Newman, D., Cole, C., Zhou, X., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.258 · Cited by 37
Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity
Wu, F., Luo, S., Zhang, Y., Ou, Y., Wang, H., Guo, Z., He, C., Bai, S., He, P., Jiang, M., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.004 · Cited by 35
Remes, A. K., Basha, D. I., Puehler, T., Borowski, C., Hille, S. S., Kummer, L., Wagner, A. H., Hecker, M., Soethoff, J. P., Lutter, G., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.017 · Cited by 35
Metadata
- Authors
- Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., & Wong, W. Y.
- Affiliations
- From Barts and the London School of Medicine and Dentistry (K.J.P.), Guy’s and St. Thomas’ NHS Foundation Trust (B.M.), and the Centre for Haematology, Imperial College London (M. Laffan), London, University Hospital Southampton, Southampton (S.R.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (W.L.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (E.S.) — all in the United Kingdom; and BioMarin Pharmaceutical, Novato (N.M., C.B.R., M. Li, W.Y.W.), and private...
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-02
- Volume
- 382
- Issue
- 1
- Pages
- 29-40
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2998050720
- Cited by
- 448
- References
- 29
- Citations by year
- 2026: 30 · 2025: 52 · 2024: 59 · 2023: 67 · 2022: 96 · 2021: 71 · 2020: 73
- FWCI
- 48.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- BioMarin Pharmaceutical
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, adeno-associated virus gene therapy, factor VIII, long-term safety, annualized bleeding rate, transgene expression kinetics
- MeSH terms
- Dependovirus, Adult, Coagulants, Factor VIII, Follow-Up Studies, Genetic Vectors, Hemophilia A, Hemorrhage, Humans, Infusions, Intravenous, Male, Middle Aged, Genetic Therapy, Biomarkers, Transgenes, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.